A year and a half after initial recommendations, a study in The Lancet revisited the data and concluded remdesivir does not work and causes kidney and liver toxicities.

Nov 7, 2026

Previously: A year and a half after initial recommendations, a study in The Lancet revisited the data and concluded remdesivir does not work and causes kidney and liver toxicities. [Distorted]: Dr. McCullough is right that the WHO advised against remdesivir in November 2020. The final WHO Solidarity results, published in The Lancet in 2022, did find no significant overall drop in deaths. But that paper did not conclude remdesivir causes kidney and liver toxicity, and it did not say the drug should never have been used. It reported a small reduction in death or progression to a ventilator among patients who were not yet on one. This would be wrong if the 2022 Lancet Solidarity paper itself reported kidney or liver toxicity as a finding or said remdesivir should never have been used.

Now: A year and a half after initial recommendations, a study in The Lancet revisited the data and concluded remdesivir does not work and causes kidney and liver toxicities. [Distorted]: McCullough correctly recalls WHO's initial recommendation against remdesivir. The final Solidarity report found no statistically significant overall mortality reduction, but reported a small benefit in non-ventilated patients and did not conclude it should never have been used. Its findings cannot support the categorical toxic-and-useless description. WHO later changed guidance for selected high-risk patients.

Replace the news summary with the trial itself and retain its subgroup and uncertainty.